Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease (Q37511121)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 March 2009

Language	Label	Description	Also known as
English	Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease	scientific article published on 16 March 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1 reference

based on heuristic

inferred from title

author name string

Leonardo Magro

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Mohamad Mohty

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Benoit Catteau

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Valérie Coiteux

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Patrice Chevallier

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Louis Terriou

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Jean-Pierre Jouet

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Ibrahim Yakoub-Agha

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

0 references

publication date

16 March 2009

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

114

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

719-722

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

23 August 2017

Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

23 August 2017

The management and outcome of chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

23 August 2017

Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

23 August 2017

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

23 August 2017

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

26 June 2018

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5162701

2 September 2018

Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic graft versus host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current management of GIST

1 reference

https://pubmed.ncbi.nlm.nih.gov/19289852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2009-02-204750

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37511121&oldid=2104421189"